Vanderbilt-ingram Cancer Center
Clinical trials sponsored by Vanderbilt-ingram Cancer Center, explained in plain language.
-
A shot at safer CAR t: early brain protection for lymphoma patients?
Disease control Not yet recruitingThis trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Glowing cancer cells: a new way to see tumors during surgery?
Diagnosis Not yet recruitingThis trial tests whether two imaging agents, Panitumumab-IRDye800 and [18F]NOTA-ABY-030, are safe and useful for helping surgeons identify head and neck tumors and cancer-containing lymph nodes during surgery. Adults with head and neck squamous cell carcinoma who are scheduled fo…
Phase: PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Can a pill rewrite the genetic story of resistant kidney cancer?
Knowledge-focused Not yet recruitingThis pilot study tests whether the experimental drug casdatifan can alter the activity of genes controlled by HIF-2α in people with advanced clear cell kidney cancer that has stopped responding to prior treatments. Participants take casdatifan daily, and researchers analyze tumor…
Phase: EARLY_PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a glowing drug light up head and neck tumors?
Knowledge-focused Not yet recruitingThis early-phase trial is testing whether injecting a fluorescently labeled version of the immunotherapy drug nivolumab directly into head and neck tumors is safe and helps visualize the tumor and nearby lymph nodes during surgery. Adults with head and neck squamous cell carcinom…
Phase: EARLY_PHASE1 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC